Clinical Trial Update: TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma [NA]

View source ↗

Summary

A clinical trial update indicates a study evaluating transarterial chemoembolization (TACE) combined with lenvatinib and a PD-1 inhibitor for hepatocellular car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• PD-1 inhibitor

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization | NA | Status: RECRUITING